Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart

Key Stats

Today's Range
$4.34
$4.34
50-Day Range
$4.30
$4.41
52-Week Range
$1.39
$4.58
Volume
N/A
Average Volume
95,984 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.63
Consensus Rating
Buy

Company Overview

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Lumos Pharma reports sustained growth in PGHD trials
Lumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its earnings results on Thursday, November, 7th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.34. The firm earned $0.73 million during the quarter, compared to analysts' expectations of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
7/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
CIK
1126234
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$4.25
Potential Upside/Downside
+98.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%
Return on Equity
-233.03%
Return on Assets
-129.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.66
Quick Ratio
2.66

Sales & Book Value

Annual Sales
$2.21 million
Price / Sales
17.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Outstanding Shares
8,649,000
Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners